Sarcoma  >>  sirolimus  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sirolimus / Generic mfg.
NCT00672243: Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Completed
2
32
US
Erlotinib + sirolimus, sirolimus - Rapamune, erlotinib - Tarceva - OSI-774
Duke University, Genentech, Inc., OSI Pharmaceuticals
Glioblastoma, Gliosarcoma
09/08
12/09
HopES, NCT03778996: SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Active, not recruiting
2
31
US
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), SM-88
Sarcoma Oncology Research Center, LLC, Tyme, Inc
Sarcoma, Ewing, Sarcoma
12/24
03/25
SARC023, NCT02008877: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Completed
1/2
20
US
ganetespib, STA-9090, Sirolimus, Rapamycin
Sarcoma Alliance for Research through Collaboration, Synta Pharmaceuticals Corp., United States Department of Defense
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
04/18
07/18
NCT01265030: A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis

Completed
1/2
9
US
Sirolimus, Rapamune®, Rapamycin
MaineHealth, Desmoid Tumor Research Foundation, Pfizer
Desmoid Tumor
12/21
12/21

Download Options